We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue. Learn more OK
Roche Australia Menu Search : Xofluza Roche Australia

You are here:

  1. What we do
  2. Pharmaceuticals
  3. Xofluza
  • Home
  • Roche in Australia
  • What we do
  • Sustainability
  • Our innovation
  • Supporting patients
  • Healthcare Professionals
  • News & Publications
  • Perspectives
  • Working at Roche
  • Contact

Pharmaceutical Product Information

Xofluza® (baloxavir marboxil)

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Share
  • Share via email
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Google+
  • Share on Xing
Close

View all products

  • © 2020 Roche Australia
  • 09.03.2020

Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report an adverse event (side effect) associated with a Roche medicinal product, please contact the Roche Australia Drug Safety Department immediately on [email protected] or on +61 (0)2 9454 9444. Roche acknowledges the Traditional Owners of Country throughout Australia. We pay our respects to Elders past and present.

  • Find us on LinkedIn